Part-Time
Lab Analyst 1
Posted on 11/1/2025
Icon
10,001+ employees
Global drug and device development services
No salary listed
Company Does Not Provide H1B Sponsorship
San Antonio, TX, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Associate or bachelor’s degree in medical laboratory science.
- MT/MLT/ASCP required (Clinical Lab Scientist license)
- Minimum 2 years in a laboratory environment, preferably in a clinical pathology laboratory or related industry.
- Proficient in laboratory techniques
- Good communication skills and the ability to work effectively in a team environment.
- Under general supervision, Performs and reports routine and special laboratory tests on clinical trial specimens to aid in subject safety and in accordance to protocol requirements.
- Detect abnormalities as indicated in protocol.
- Performs specimen processing and testing independently to include waived and moderate complexity testing. Analyzes test results and assumes accountability for accuracy.
- Operates, maintains, and troubleshoots laboratory instrumentation and equipment and makes minor repairs as necessary and knows when to notify lab management.
- Understands, performs, and practices quality control management to include running controls, evaluating data, documentation of data, and taking corrective action as required. Communicates any relevant QC information to Supervisor or Manager.
- Must cross-train to other laboratory sections as needed.
- Calculates, enters, and/or verifies results of laboratory procedures.
- Utilizes the Laboratory Information System and eSource system.
- Provides notification and documentation of critical laboratory values obtained to Principal Investigator.
- Participates in the evaluation, development, and implementation of new or updated testing procedures and protocols.
- Demonstrates competence to perform laboratory testing.
- Demonstrates adherence to ICON Own It Values based on Integrity, Inclusion, Agility, Collaboration.
- Must complete all required compliance and regulatory tasks and follow all applicable policies and procedures.
- Performs other duties as assigned.
Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Advarra integration reduces administrative friction and accelerates study startups.
- Oncology expansion adds 14 oncologists to boost patient recruitment.
- Jefferies upgrades ICON to Buy with $135 target post-selloff.
What critics are saying
- Audit probe reveals $160M revenue overstatements, delaying Q4 2025 results to April 30.
- Holzer & Holzer, Levi & Korsinsky lawsuits erode investor confidence immediately.
- IQVIA captures 20% more biotech trials via superior AI site selection.
What makes Icon unique
- ICON partners with Advarra on March 24, 2026, for connected site network using Braid AI.
- Accellacare expands oncology via Brian Moran Cancer Institute partnership in Illinois.
- Deepali Suri leads biotech division since September 2025 with AI-enabled solutions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↓ -13%1 year growth
↓ -13%2 year growth
↓ -13%Icon, Advarra partnership aims to optimize trials, expand access. * March 24, 2026 Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials. Fields (*) Mark are Required
ICON plc and Advarra have partnered to introduce a "research-ready" connected site network model for clinical trials. The partnership integrates ICON's global clinical trial solutions with Advarra's site systems, already used by over 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres. The collaboration will create a shared operating environment that reduces administrative burden, accelerates study startup and increases clinical trial participation. Advarra will provide operational intelligence through its Braid AI platform to help ICON optimise protocol design and improve site identification. The companies plan to equip emerging and research-naïve sites with Advarra's technology, enabling broader geographic diversity in clinical trials. Last year, Advarra's systems managed over $4 billion in trial invoice value and three million patient visits.
ICON, Advarra partner on connected site network model. Partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. March 24, 2026 Managing Editor, Contract Pharma ICON plc, a clinical research organization, and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new 'research-ready,' connected site network model for clinical trials. The partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. This approach leverages Advarra's Study Collaboration as the connector to ICON's technology to create a shared operating environment for ICON studies that aims to reduce administrative friction, accelerate study startup, and increase clinical trial participation. Advarra will also provide ICON with operational intelligence through Study Collaboration, built on Braid, Advarra's data and AI platform that draws on operational insights from its IRB and clinical trial systems. The intelligence will help ICON further optimize protocol design, improve forecasting and study planning, and strengthen research site identification and feasibility decisions. With a clearer understanding of research site capacity, workflow realities, and historical operational patterns, the goal is to allow for studies to be planned more realistically and executed with fewer downstream adjustments. In addition, ICON and Advarra will work together to expand access to clinical trials by enabling more research sites worldwide to support today's increasingly complex study requirements. The companies plan to equip emerging and research-naïve sites, along with select sites working with ICON, with Advarra's site technology, helping standardize operations and reduce manual processes. "Research sites should not have to adapt their operations for every new study or sponsor, and ICON and Advarra are focused on meeting sites where they are, prioritising their needs and removing that burden through this partnership," said Barry Balfe, CEO of ICON plc. "By aligning ICON's workflows with the systems sites already use every day, we're advancing a more practical and scalable way to run trials that reduces administrative burden on sites." "Sites do their best work when they can stay focused on patients and study delivery, not on managing fragmented processes," said Gadi Saarony, CEO of Advarra. "By integrating ICON's technology with the Advarra systems sites already use, this partnership allows sites to work in their native systems, reducing rework, improving consistency, and streamlining workflows. For sponsors, it means trials can move forward with greater speed and confidence, helping promising therapies move through development more efficiently and reach patients sooner."
Jefferies has upgraded ICON Public Limited Company to Buy from Hold, lowering its price target to $135 from $175. Analyst David Windley cited the stock's valuation as "hard to ignore", noting that whilst AI could compress labour-intensive businesses, the market may underestimate regulatory hurdles to rapid tech adoption. The upgrade follows TD Cowen's recent move to Buy from Hold with a $120 price target, describing the risk-reward as "compelling" after a 33% selloff tied to an internal accounting investigation. ICON disclosed in February that preliminary findings indicate revenue for 2023 and 2024 may have been overstated by less than 2% each year. The company withdrew its 2025 guidance and plans to release fourth-quarter results by 30th April.
ICON plc, one of the world's largest contract research organisations, is facing investigation after disclosing on 12 February that an internal accounting probe uncovered preliminary evidence of revenue overstatements by up to 2% in fiscal years 2023 and 2024. The disclosure prompted the company to delay releasing its fourth-quarter and full-year 2025 financial results. With reported annual revenue exceeding $8 billion, a 2% overstatement would represent approximately $160 million per year. Following the announcement, ICON shares declined roughly 40%, erasing billions in market capitalisation. Law firm Levi & Korsinsky is investigating the Dublin-based company, which provides outsourced drug development and clinical trial management services. During 2025, ICON repurchased $750 million of its own shares and authorised an additional $1 billion buyback programme.